哮喘全球防治倡议(GINA)建议儿童及成年初诊哮喘患者均应接受含 ICS 的药物治疗,以获得最佳疗效;不推荐单用短效 β2 受体激动剂(SABA)。对于轻度哮喘,与单用 SABA 相比,按需使用低剂量的 ICS/福莫特罗使急性发作或住院风险下降 2/3。 对于轻...
哮喘全球防治倡议(GINA)建议儿童及成年初诊哮喘患者均应接受含 ICS 的药物治疗,以获得最佳疗效;不推荐单用短效 β2 受体激动剂(SABA)。对于轻度哮喘,与单用 SABA 相比,按需使用低剂量的 ICS/福莫特罗使急性发作或住院风险下降 2/3。 对于轻度哮喘,推荐使用低剂量 ICS 或按需给予低剂量 ICS/福莫特罗,以降低急性...
哮喘是一种慢性气道炎症性疾病,ICS 是治疗哮喘的基础!哮喘全球防治倡议(GINA)建议儿童及成年初诊哮喘患者均应接受含 ICS 的药物治疗,以获得最佳疗效;不推荐单用短效 β2 受体激动剂(SABA)。对于轻度哮喘,与单用 SABA 相比,按需使用低剂量的 ICS/福莫特罗使急性发作或住院风险下降 2/3。 对于轻度哮喘,推荐使用低...
单一维持和缓解治疗(The Single Maintenance and Reliever Therapy, SMART or MART)策略,建议ICS联合速效LABA作为维持治疗以及缓解症状的缓解治疗(比如,低剂量布地奈德-福莫特罗或者倍氯米松-福莫特罗)。另一种方案是ICS/LABA联合吸入,加用一种短效β受体激动剂(short act...
Because of limited guidance on the use of the ICS-SABA reliever inhaler in older adults, the purpose of this review is to evaluate the DENALI and MANDALA studies and the potential role of ICS-SABA in older adults. The mean ages in both studies were 50 years. The MANDALA pr...
An alternative to combination ICS/albuterol reliever treatment is the use of separate ICS and SABA inhalers at the same time as reliever therapy. There is an evidence base for the efficacy and safety of this approach in both children and adults; however, there is a major practical limitation ...
forced expiratory volume in 1 s; FeNO: fraction of exhaled nitric oxide; GERD: gastro-esophageal reflux disease; ICS: inhaled corticosteroids; IQR: interquartile range; IL: interleukin; IgE: immunoglobulin E; LABA: long-acting beta-agonist; SABA: short-acting beta- agonist; YKL-40: human ...
而在此次会议上,loana Agache教授及其团队提出PICO 2(图1):Is as-needed ICS/formoterol (single inhaler) without maintenance treatment the preferred treatment compared to as-needed SABA without maintenance treatment in adult/adolescent patients with mild asthma,讲述研究结果,并结合最佳科学证据为轻度哮喘患者...
SABA was categorised by number of inhalers/year. ICS was defined as mean-daily-dose/year (beclomethasone equivalent); year-to-year increases/decreases were defined as ≥200mcg.Results: 373,256 mild asthma patients were identified. During the study period the approximate percentage of patients ...
They call for more research in children aged 4-11 years and propose the immediate implementation of strategies to replace SABA inhalers with ICS-formoterol therapy for individuals over the age of 12. They emphasize the need for a comprehensive approach to asthma management, including ...